Mary Hauser

575 total citations
20 papers, 327 citations indexed

About

Mary Hauser is a scholar working on Cellular and Molecular Neuroscience, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, Mary Hauser has authored 20 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cellular and Molecular Neuroscience, 6 papers in Pharmacology and 6 papers in Psychiatry and Mental health. Recurrent topics in Mary Hauser's work include Neurotransmitter Receptor Influence on Behavior (10 papers), Attention Deficit Hyperactivity Disorder (6 papers) and Substance Abuse Treatment and Outcomes (5 papers). Mary Hauser is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (10 papers), Attention Deficit Hyperactivity Disorder (6 papers) and Substance Abuse Treatment and Outcomes (5 papers). Mary Hauser collaborates with scholars based in United States, India and Hungary. Mary Hauser's co-authors include Kenneth Blum, David Siwicki, Rajendra D. Badgaiyan, John Giordano, Thomas Simpatico, Debmalya Barh, John Femino, Edward J. Modestino, Eric R. Braverman and Thomas J.H. Chen and has published in prestigious journals such as Molecular Neurobiology, Substance Use & Misuse and American Journal on Addictions.

In The Last Decade

Mary Hauser

20 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Hauser United States 11 152 110 86 74 49 20 327
Siobhan Morse United States 9 122 0.8× 91 0.8× 58 0.7× 45 0.6× 57 1.2× 18 308
Rosa Jurado‐Barba Spain 13 118 0.8× 81 0.7× 107 1.2× 92 1.2× 127 2.6× 50 482
Karolina Kozak Canada 8 74 0.5× 95 0.9× 57 0.7× 107 1.4× 110 2.2× 14 374
Romain Icick France 12 56 0.4× 147 1.3× 56 0.7× 101 1.4× 42 0.9× 42 351
Juris P. Mezinskis United States 8 228 1.5× 122 1.1× 122 1.4× 45 0.6× 37 0.8× 8 368
Alexandria S. Coles Canada 8 56 0.4× 136 1.2× 170 2.0× 104 1.4× 83 1.7× 14 457
Darby J. E. Lowe Canada 7 67 0.4× 110 1.0× 168 2.0× 124 1.7× 61 1.2× 12 409
Elena Ros‐Cucurull Spain 12 100 0.7× 164 1.5× 61 0.7× 163 2.2× 48 1.0× 40 428
Emi Shufman Israel 9 94 0.6× 83 0.8× 56 0.7× 64 0.9× 38 0.8× 17 317
Rebecca M. Harley United States 6 84 0.6× 53 0.5× 61 0.7× 117 1.6× 28 0.6× 7 361

Countries citing papers authored by Mary Hauser

Since Specialization
Citations

This map shows the geographic impact of Mary Hauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Hauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Hauser more than expected).

Fields of papers citing papers by Mary Hauser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Hauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Hauser. The network helps show where Mary Hauser may publish in the future.

Co-authorship network of co-authors of Mary Hauser

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Hauser. A scholar is included among the top collaborators of Mary Hauser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Hauser. Mary Hauser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boyett, Brent, Rajendra D. Badgaiyan, Panayotis K. Thanos, et al.. (2020). Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. PubMed. 6(1). 1–4. 7 indexed citations
2.
Galanter, Marc, John Femino, Brooke D. Hunter, & Mary Hauser. (2020). Buprenorphine Treatment for Opioid Use Disorder in Community‐Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results. American Journal on Addictions. 29(4). 271–278. 4 indexed citations
3.
4.
Blum, Kenneth, David Baron, Lisa Lott, et al.. (2019). In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The “Holy Grail” in Genetic Addiction Risk Testing. PubMed. 9(1). 7–21. 20 indexed citations
5.
Blum, Kenneth, Marjorie C. Gondré‐Lewis, Edward J. Modestino, et al.. (2019). Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization. Molecular Neurobiology. 56(11). 7836–7850. 25 indexed citations
6.
7.
8.
Blum, Kenneth, Edward J. Modestino, Marjorie C. Gondré‐Lewis, et al.. (2018). The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD).. PubMed. 2018(1). 23 indexed citations
9.
Blum, Kenneth, Edward J. Modestino, Marjorie C. Gondré‐Lewis, et al.. (2018). The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD). 3(1). 8 indexed citations
10.
Blum, Kenneth, Lisa Lott, David Siwicki, et al.. (2018). Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis.. PubMed. 1(1). 12 indexed citations
11.
12.
Blum, Kenneth, Edward J. Modestino, Bernard W. Downs, et al.. (2017). “Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic. PubMed. 3(6). 15 indexed citations
13.
Blum, Kenneth, Edward J. Modestino, Marjorie C. Gondré‐Lewis, et al.. (2017). GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA.. PubMed. 2(1). 17–22. 14 indexed citations
14.
Blum, Kenneth, et al.. (2015). Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. PubMed. 2(1). 1–5. 6 indexed citations
15.
Blum, Kenneth, David K. Han, Marlene Oscar‐Berman, et al.. (2013). Iatrogenic opioid dependence is endemic and legal: Genetic addiction risk score (GARS) with electrotherapy a paradigm shift in pain treatment programs. Health. 5(11). 16–34. 1 indexed citations
16.
Blum, Kenneth, M. Foster Olive, Kevin Wang, et al.. (2013). Hypothesizing that designer drugs containing cathinones (“bath salts”) have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. Medical Hypotheses. 81(3). 450–455. 22 indexed citations
17.
Blum, Kenneth, David Han, Mary Hauser, et al.. (2013). NEUROGENETIC IMPAIRMENTS OF BRAIN REWARD CIRCUITRY LINKS TO REWARD DEFICIENCY SYNDROME (RDS) AS EVIDENCED BY GENETIC ADDICTION RISK SCORE (GARS): A CASE STUDY. 4(1). 4–9. 8 indexed citations
18.
Blum, Kenneth, Amanda LC Chen, John Giordano, et al.. (2012). The Addictive Brain: All Roads Lead to Dopamine. Journal of Psychoactive Drugs. 44(2). 134–143. 83 indexed citations
19.
Hauser, Mary. (1975). Initiation into Peer Review. AJN American Journal of Nursing. 75(12). 2204–2204. 5 indexed citations
20.
Hauser, Mary, et al.. (1975). The Head Nurse: Her Leadership Role. AJN American Journal of Nursing. 75(11). 2082–2082. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Siobhan Morse Breakdown of academic impact, for papers by Rosa Jurado‐Barba Breakdown of academic impact, for papers by Karolina Kozak Breakdown of academic impact, for papers by Romain Icick Breakdown of academic impact, for papers by Juris P. Mezinskis Breakdown of academic impact, for papers by Alexandria S. Coles Breakdown of academic impact, for papers by Darby J. E. Lowe Breakdown of academic impact, for papers by Elena Ros‐Cucurull Breakdown of academic impact, for papers by Emi Shufman Breakdown of academic impact, for papers by Rebecca M. Harley
Rankless by CCL
2026